Non-Hodgkin's lymphomas, version 2.2014.

Abstract

Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Follicular lymphoma (FL) is the most common subtype of indolent NHL, accounting for approximately 22% of all newly diagnosed cases of NHL. The incorporation of rituximab to chemotherapy regimens has become a widely accepted standard of care for first-line therapy for patients with FL. Maintenance and consolidation therapy with rituximab and radioimmunotherapy have also been associated with improved progression-free survival in patients experiencing response to first-line therapy. Despite therapeutic advances that have improved outcomes, FL is generally considered a chronic disease characterized by multiple recurrences with current therapies. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with FL.

• Authors: Andrew D Zelenetz, Leo I Gordon, William G Wierda, Jeremy S Abramson, Ranjana H Advani, C Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C Byrd, Myron S Czuczman, Luis E Fayad, Richard I Fisher, Martha J Glenn, Nancy Lee Harris, Richard T Hoppe, Steven M Horwitz, Christopher R Kelsey, Youn H Kim, Susan Krivacic, Ann S LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Lubomir Sokol, Lode J Swinnen, Christina Tsien, Julie M Vose, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, Hema Sundar
• Journal: Journal of the National Comprehensive Cancer Network : JNCCN (J Natl Compr Canc Netw) Vol. 12 Issue 6 Pg. 916-46 (Jun 2014) ISSN: 1540-1413 [Electronic] United States
• PMID: 24925202 (Publication Type: Guideline, Journal Article)
• Copyright: Copyright © 2014 by the National Comprehensive Cancer Network.

Chemical References

• Antibodies, Monoclonal, Murine-Derived
• Rituximab

Topics

• Antibodies, Monoclonal, Murine-Derived (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
• Disease-Free Survival
• Humans
• Lymphoma, Follicular (diagnosis, drug therapy, pathology)
• Lymphoma, Non-Hodgkin (diagnosis, drug therapy, pathology)
• Neoplasm Recurrence, Local (diagnosis, drug therapy, pathology)
• Radioimmunotherapy
• Rituximab